Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frits van Rhee

Showing results (21-30 of 274) with videos related to

Pageof 28
Sort By:
Mayo Clinic Proceedings|April 7, 2018
Daratumumab for POEMS SyndromeMaliha Khan, Katie Stone, Frits van Rhee
The New England Journal of Medicine|June 22, 2007
Allografting or autografting for myelomaFrits van Rhee, John Crowley, Bart Barlogie
Oncotargets and Therapy|June 26, 2023
Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current PerspectivesTrilok Shrivastava, Frits Van Rhee, Samer Al Hadidi
Blood and Lymphatic Cancer : Targets and Therapy|May 26, 2015
Profile of elotuzumab and its potential in the treatment of multiple myelomaYi-Chang Liu, Susann Szmania, Frits van Rhee
The Oncologist|November 23, 2023
Perspectives on the Treatment of Multiple MyelomaAbdul Rafae, Frits van Rhee, Samer Al Hadidi
American Journal of Clinical Pathology|March 3, 2026
Elucidating the grading intricacies of idiopathic multicentric Castleman disease histopathology: a pathologist's perspectiveDaisy V Alapat, Payam Etebari, Frits Van Rhee
JAMA Oncology|April 28, 2022
Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential SolutionsSamer Al Hadidi, Maurizio Zangari, Frits van Rhee
Expert Review of Hematology|August 12, 2014
Siltuximab for multicentric Castleman diseaseYi-Chang Liu, Katie Stone, Frits van Rhee
Therapeutic Advances in Hematology|March 7, 2022
Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case reportEvan Lang, Brenda Sande, Samantha Brodkin, et al.
Blood|May 1, 2026
How I Treat Plasma Cell LeukemiaSamer Al Hadidi, Frits van Rhee, Larry D Anderson
Pageof 28

Showing results (21-30 of 274) with videos related to

Sort By:
Pageof 28
Mayo Clinic Proceedings|April 7, 2018
Daratumumab for POEMS SyndromeMaliha Khan, Katie Stone, Frits van Rhee
The New England Journal of Medicine|June 22, 2007
Allografting or autografting for myelomaFrits van Rhee, John Crowley, Bart Barlogie
Oncotargets and Therapy|June 26, 2023
Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current PerspectivesTrilok Shrivastava, Frits Van Rhee, Samer Al Hadidi
Blood and Lymphatic Cancer : Targets and Therapy|May 26, 2015
Profile of elotuzumab and its potential in the treatment of multiple myelomaYi-Chang Liu, Susann Szmania, Frits van Rhee
The Oncologist|November 23, 2023
Perspectives on the Treatment of Multiple MyelomaAbdul Rafae, Frits van Rhee, Samer Al Hadidi
American Journal of Clinical Pathology|March 3, 2026
Elucidating the grading intricacies of idiopathic multicentric Castleman disease histopathology: a pathologist's perspectiveDaisy V Alapat, Payam Etebari, Frits Van Rhee
JAMA Oncology|April 28, 2022
Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential SolutionsSamer Al Hadidi, Maurizio Zangari, Frits van Rhee
Expert Review of Hematology|August 12, 2014
Siltuximab for multicentric Castleman diseaseYi-Chang Liu, Katie Stone, Frits van Rhee
Therapeutic Advances in Hematology|March 7, 2022
Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case reportEvan Lang, Brenda Sande, Samantha Brodkin, et al.
Blood|May 1, 2026
How I Treat Plasma Cell LeukemiaSamer Al Hadidi, Frits van Rhee, Larry D Anderson
Pageof 28